TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02598635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Patients on peritoneal dialysis and 25-(OH) levels \<20 ng/mL will received one capsule of cholecalciferol (4800 U) once a day for 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks.
Study: NCT00634413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline - ADC4022
Description: Inhaled theophylline (ADC4022) administered twice daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled matching placebo administered twice daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhaled budesonide twice daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide
Description: Inhaled budesonide twice daily for 28 days
Study: NCT01161511

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb5574
Description: Intravenous infusion of XmAb5574 administered weekly during two 28-day cycles with an additional dose being administered during the first week of Cycle 1. (Cycle 1 on Days 1, 4, 8, 15, 22; Cycle 2 on Days 1, 8, 15, 22)
Study: NCT04305132

Intervention type: DEVICE
Intervention: Electroconvulsive therapy
Description: Thymatron System IV electroconvulsive therapy device
Study: NCT04588701

Intervention type: PROCEDURE
Intervention: surgical procedures commonly done for anal fistula
Description: Surgical procedures performed, including fistulotomy; fistulotomy with sphincter repair; seton; advancement flap; fistula plug;
Study: NCT02881398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth
Description: After randomization and at the time of the initial encounter, study subjects are assessed at the point-of-care with mHealth devices that measure symptoms, functional status, and for structural abnormalities. These devices include activity monitoring for an assessment of a 6-minute walk test, smartphone connected blood pressure, oxymetry and ECG for functional assessments, and structural assessments with handheld-echocardiography and point-of-care BNP. Treatment decisions for an intervention with percutaneous valvuloplasty or valve replacement were performed based on the aggregate of these mHealth findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-Care
Description: After randomization and at the time of the initial encounter, study subjects randomized to standard-care underwent a physical examination, 12-lead ECG, radiographic and laboratory tests as warranted and clinically required. Treatment decisions for percutaneous valvuloplasty or valve replacement were based on the aggregate of the standard-care findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
Study: NCT01385137

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT03627117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verum
Description: Single vape of 0.25mL of CBD e-Liquid containing: 5% CBD (low-temperature extracted Cannabidiol from Cannabis sativa L., purity 99%), Glycerine (vegetable), Propylene glycol, water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verum
Description: Single vape of 0.25mL of CBD e-Liquid containing: 5% CBD (low-temperature extracted Cannabidiol from Cannabis sativa L., purity 99%), Glycerine (vegetable), Propylene glycol, water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single vape of 0.25ml e-liquid La Baronne Jaune, BORDO2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single vape of 0.25ml e-liquid La Baronne Jaune, BORDO2.
Study: NCT02056431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVR Intervention Group
Description: Participants will receive 3 interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) to collect information on medication use, side effects, rating of side effects, and pain symptoms to be fed back to their physicians.
Study: NCT03620760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 mg
Description: Ticagrelor (AZD6140) 90 mg twice daily dose
Study: NCT00062244

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study: NCT01313559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pasireotide
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory biomarker analysis
Description: Correlative studies
Study: NCT03620760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 45 mg
Description: Ticagrelor (AZD6140) 45 mg twice daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 100 mg once daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg once daily dose
Study: NCT01491373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS/LT-CAGE® Device
Description: rhBMP-2/ACS inserted into Sofamor Danek's LT-CAGE® device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft/LT-CAGE® Device
Description: LT-CAGE® device filled with autogenous bone taken from the patient's iliac crest
Study: NCT00673439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fondaparinux
Description: Dosage form: subcutaneous injection; dosage: 7.5 to 10.0 mg; frequency and duration: daily until blood test results rule out confirmed HIT - for patients with confirmed HIT, continue daily until INR (blood clotting) measurement rises to at least 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: Dosage form: oral; dosage: 2.5 to 5.0 mg; frequency and duration: (for confirmed HIT only) once daily, to begin when blood platelet count reaches at least 100,000, and continue for approximately 4 weeks
Study: NCT03449732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDR measurement
Description: PDR measurement at two standardized times perioperatively:~1. Anesthetized subject by sevoflurane sedation until a minimum alveolar concentration (MAC) of at least 1,5 is reached~2. Administration of fentanyl 2µg/kg, in the absence of adjustments in sedation depth

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDR measurement
Description: PDR measurement at two standardized times perioperatively:~1. Anesthetized subject by sevoflurane sedation until a minimum alveolar concentration (MAC) of at least 1,5 is reached~2. Administration of fentanyl 2µg/kg, in the absence of adjustments in sedation depth

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDR measurement
Description: PDR measurement at two standardized times perioperatively:~1. Anesthetized subject by sevoflurane sedation until a minimum alveolar concentration (MAC) of at least 1,5 is reached~2. Administration of fentanyl 2µg/kg, in the absence of adjustments in sedation depth
Study: NCT03911232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: standard general anesthesia protocol with sugammadex
Study: NCT01723800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K inhibitor BKM120
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02802137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tafluprost
Study: NCT01723800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT05328739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home care
Description: home care program
Study: NCT02010957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDG positron emission tomography
Description: 2 consecutive imaging studies (diagnostic study) within 1-2 weeks: FDG-PET and 123I-Iodometomidate imaging in patients with an indeterminate adrenal neoplasm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodometomidate imaging
Description: 2 consecutive imaging studies (diagnostic study) within 1-2 weeks: FDG-PET and 123I-Iodometomidate imaging in patients with an indeterminate adrenal neoplasm
Study: NCT01391858

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lyrica
Description: 150mg of pregabalin/placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lyrica
Description: 150mg of pregabalin/placebo
Study: NCT01313559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Description: Correlative studies
Study: NCT02802137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tafluprost and dorzolamide/timolol
Study: NCT00358735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiveCare CECT device
Description: Patients will be treated with the ActiveCare+ CECT device starting after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery. Baby aspirin (81 mg) QD can be added (depending on surgeon preference) 12-24 hours after surgery. Post discharge prophylaxis is the same for the remainder of the 10-12 days. Patients will wear the device to the duplex ultrasound when it will be discontinued by nurse.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Patients will be treated with Enoxaparin (Lovenox) for a total of 10 days beginning with 30mg BID starting 12-24 hours after surgery and continued until hospital discharge. Post discharge prophylaxis will be Enoxaparin 40mg QD for the remainder of the 10 days.
Study: NCT02297152

Intervention type: DEVICE
Group type: OTHER
Intervention: FLIP HOLE
Description: The subjects had to use the masturbator aid at least five times per week for six weeks, during a minimum of five minutes without never overcoming half daily hour and during intercourse. The device Flip Hole is a masturbation aid made from Thermoplastic Elastomer (a silicone like substance) that the user inserts their penis in to for stimulation.
Study: NCT01817972

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab pegol
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Certolizumab pegol
Description: Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: 50mg tablets
Study: NCT01032941

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: Patients in this group will be given the probiotic VSL#3 2 packets BID for a total of 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Patients in this group will be given the probiotic VSL#3 2 packets BID for a total of 8 weeks.
Study: NCT04157829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scintilling lamp
Description: Lamp with a standardized scintilling

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scintilling lamp
Description: Lamp with a standardized scintilling

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Classic lamp
Description: Lamp without a scintilling
Study: NCT03313154

Intervention type: OTHER
Intervention: Neuropsychiatric screening
Description: Psychiatric diagnosis through:~1. clinical interview~2. the Advanced Neuropsychiatric Tools and Assessment Schedule (ANTAS), based on the SCID-I-NP (Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders-Non Patient Version);~3. HAM-D (Hamilton Scale for Depression);~4. PHQ-9 (Patient's Health Questionnaire-9 items);~5. MDQ (Mood Disorders Questionnaire);~6. YMRS (Young Mania Rating Scale);~7. ASRM (Altman Self Rating Mania scale);~8. BRIAN (Biological Rhythms Interview of Assessment in Neuropsychiatry).~   Assessment of Quality of Life:~9. SF-12 (Short Form Health Survey-12 items).~Neuropsychological screening:~l) Addenbrooke's Cognitive Examination (ACE-R).

Intervention type: OTHER
Intervention: Neuropsychiatric screening
Description: Psychiatric diagnosis through:~1. clinical interview~2. the Advanced Neuropsychiatric Tools and Assessment Schedule (ANTAS), based on the SCID-I-NP (Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders-Non Patient Version);~3. HAM-D (Hamilton Scale for Depression);~4. PHQ-9 (Patient's Health Questionnaire-9 items);~5. MDQ (Mood Disorders Questionnaire);~6. YMRS (Young Mania Rating Scale);~7. ASRM (Altman Self Rating Mania scale);~8. BRIAN (Biological Rhythms Interview of Assessment in Neuropsychiatry).~   Assessment of Quality of Life:~9. SF-12 (Short Form Health Survey-12 items).~Neuropsychological screening:~l) Addenbrooke's Cognitive Examination (ACE-R).
Study: NCT01150409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: 1) Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
Study: NCT02102529

Intervention type: PROCEDURE
Intervention: laparoscopic colonic surgery
Description: women with typical symptoms including pelvic pain, infertility and endometriotic bowel lesions who underwent laparoscopic surgery including colonic resection performed from 2009 to 2012
Study: NCT06568991

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low Protein Rice MATSUBUMAI
Description: Investigators will recruit 100 subjects participating in thePRE-ESRD education plan at KMUH. Subjects will receive dietary education of low protein diet (providing energy 25 to 35 Kcal/Kg/day, protein 0.6 to 0.8 g/Kg/day) by dietitians. Subjects will be randomly assigned to a observational group or rue low protein rice group.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Protein Rice MATSUBUMAI
Description: Investigators will recruit 100 subjects participating in thePRE-ESRD education plan at KMUH. Subjects will receive dietary education of low protein diet (providing energy 25 to 35 Kcal/Kg/day, protein 0.6 to 0.8 g/Kg/day) by dietitians. Subjects will be randomly assigned to a observational group or rue low protein rice group.
Study: NCT03622086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foundations of Fitness Program
Description: The Foundations of Fitness Program is a 12 week, bi-weekly community intensive lifestyle program which focuses on healthy diet, daily physical activity, self-esteem and support for individual and family behavior change, components supported by USPSTF evidence review. Class sessions, which involve both parent/caregiver and child will include structured fitness activities, hands on nutrition, cooking, shopping and meal planning and facilitated discussions about goal setting, self-monitoring, stimulus control and healthy homes and families. Content will be offered in a context that supports self-esteem and behavior change. The program was developed by the Carter Community Building Association (CCBA) in collaboration with the Dartmouth-Hitchcock Weight \& Wellness Center research core.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foundations of Fitness Program
Description: The Foundations of Fitness Program is a 12 week, bi-weekly community intensive lifestyle program which focuses on healthy diet, daily physical activity, self-esteem and support for individual and family behavior change, components supported by USPSTF evidence review. Class sessions, which involve both parent/caregiver and child will include structured fitness activities, hands on nutrition, cooking, shopping and meal planning and facilitated discussions about goal setting, self-monitoring, stimulus control and healthy homes and families. Content will be offered in a context that supports self-esteem and behavior change. The program was developed by the Carter Community Building Association (CCBA) in collaboration with the Dartmouth-Hitchcock Weight \& Wellness Center research core.
Study: NCT04425369

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two-sided approaches for iliac crest bone graft
Description: Only one side of the ilium was exposed when surgery.
Study: NCT01803035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-109 1 %

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-109 2 %

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Study: NCT00227734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine and oxaliplatin + cetuximab
Description: cetuximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine and oxaliplatin
Description: capecitabine and oxaliplatin without cetuximab
Study: NCT01550068

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiography
Study: NCT04138602

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BTL Emsella
Description: Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham BTL Emsella
Description: Sham subjects will be seated on the device in the same manner as the active treatment group. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level ( \< 10 % power).
Study: NCT03113175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative care
Description: Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation, medication according to a stepped care model

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultations-Liaison
Description: Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
Study: NCT00886015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TT Clamp
Description: trichiasis surgery performed with TT clamp

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard BLTR Technique
Description: bilamellar tarsal rotation procedure in trichiasis surgery
Study: NCT01395147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA21004
Description: Lu AA21004 10 mg, tablets, orally, once daily for 2 weeks; reduced to 5 mg or increased to 20 mg, once daily if necessary according to the responses and symptoms of participants for up to 50 weeks.
Study: NCT06266325

Intervention type: OTHER
Intervention: There is no intervention. Exposures are predictor variables of mortality.
Description: Predictor variables of mortality will be in following categories: sociodemographic, clinical (comorbidities, treatment), caregiver-specific, functional, nutritional, cognitive, psychological/behavioural, home care, healthcare utilization, and assessment-specific information.

Intervention type: OTHER
Intervention: There is no intervention. Exposures are predictor variables of mortality.
Description: Predictor variables of mortality will be in following categories: sociodemographic, clinical (comorbidities, treatment), caregiver-specific, functional, nutritional, cognitive, psychological/behavioural, home care, healthcare utilization, and assessment-specific information.
Study: NCT01161069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03049423
Description: PF-03049423 in oral solution, 2.5 mg, given once daily for 14 days; healthy young adult volunteers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03049423
Description: PF-03049423 in oral solution, 7.5 mg, given once daily for 14 days; healthy young adult volunteers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03049423
Description: PF-03049423 in oral solution, 6 mg, given once daily for 7 days, then 12 mg given once daily for 7 days; healthy young adult volunteers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03049423
Description: PF-03049423 in oral solution, 3 mg, given once daily for 7 days, then 6 mg given once daily for 7 days; healthy elderly adult volunteers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03049423
Description: PF-03049423 in oral solution, 5 mg, given once daily for 7 days, then 10 mg given once daily for 7 days; healthy elderly adult volunteers

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in oral solution, given once daily for 14 days
Study: NCT03312244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide
Description: Pyridostigmine 180mg/day p.o.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo